Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corium Intl (CORI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 387,064
  • Shares Outstanding, K 35,740
  • Annual Sales, $ 33,020 K
  • Annual Income, $ -36,700 K
  • 36-Month Beta 1.16
  • Price/Sales 11.57
  • Price/Cash Flow 0.00
  • Price/Book 13.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.48 +44.79%
on 08/22/17
11.28 -3.99%
on 09/21/17
+3.34 (+44.59%)
since 08/21/17
3-Month
6.97 +55.38%
on 06/27/17
11.28 -3.99%
on 09/21/17
+3.45 (+46.75%)
since 06/21/17
52-Week
2.67 +305.62%
on 02/06/17
11.28 -3.99%
on 09/21/17
+4.92 (+83.25%)
since 09/21/16

Most Recent Stories

More News
Corium to Present at Upcoming Healthcare Conferences

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that...

CORI : 10.83 (+1.31%)
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - August 24, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
CORI : 10.83 (+1.31%)
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - August 24, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
CORI : 10.83 (+1.31%)
Corium to Report Third Quarter Fiscal 2017 Financial Results on Thursday, August 3, 2017

Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third quarter ended June 30, 2017 on Thursday, August 3, 2017 after the close of the U.S. financial...

CORI : 10.83 (+1.31%)
Corium International (CORI) Catches Eye: Stock Jumps 11.9%

Corium International, Inc. (CORI) moved big last session, as the company saw its shares rise almost 12% on the day.

AQXP : 13.63 (-2.92%)
CORI : 10.83 (+1.31%)
Corium to Present Clinical Results from Pilot Bioequivalence Study of Once-weekly Corplex(TM) Donepezil Transdermal System at Alzheimer's Association International Conference(R) 2017

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that...

CORI : 10.83 (+1.31%)
Corium Joins Russell 3000(R) Index

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that...

CORI : 10.83 (+1.31%)
Corium to Present at the Jefferies 2017 Global Healthcare Conference

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that...

CORI : 10.83 (+1.31%)
Amphastar (AMPH) in Focus: Stock Moves 9.7% Higher

Amphastar Pharmaceuticals (AMPH) was a big mover last session, as the company saw its shares rise almost 10% on the day.

AMPH : 16.40 (+4.86%)
CORI : 10.83 (+1.31%)
Corium Prices Follow-On Offering of Common Stock

Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the...

CORI : 10.83 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed...

See More

Support & Resistance

2nd Resistance Point 11.88
1st Resistance Point 11.36
Last Price 10.83
1st Support Level 10.23
2nd Support Level 9.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.